breaking

FDA Overhauls Drug, Biologics Leadership in Latest Reorganization

The Food and Drug Administration is reshuffling its top regulatory positions, with two acting directors departing their roles. Tracy Beth Høeg will step down as acting director of the Center for Drug Evaluation and Research, replaced by Karim Mikhail. Katherine Szarama is leaving her position as acting director of the Center for Biologics Evaluation and Research, with Michael Davis taking over. Szarama will remain at the agency. Lowell Zeta will assume the role of acting chief of staff. The reorganization comes days after former FDA Commissioner Marty Makary's resignation. The two divisions are responsible for regulating prescription drugs, including pills and vaccines. The changes reflect continued leadership instability at the agency, which oversees products accounting for roughly 20 percent of consumer spending. The Trump administration plans to nominate a permanent commissioner within weeks, pending Senate confirmation.